A carregar...
Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
SIMPLE SUMMARY: Treatment modalities for sarcoma have not changed significantly for the past few years despite 25–50% of patients experiencing relapse or progressing to metastatic diseases that become resistant to standard of care therapy, indicating an unmet need for better treatment strategies. Wh...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7697818/ https://ncbi.nlm.nih.gov/pubmed/33207697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113392 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|